Abstract IntroductionThe European Medicines Agency (EMA) has released guidance for the surveillance of adverse events of interest (AEIs) following vaccination, early in the influenza season. It is feasible to capture brand-specific AEIs using a sentinel practice network, such as the Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC).MethodUsing the RCGP RSC dataset, we identified brands for 344,542 patients receiving the seasonal influenza from 01/09/2016 to 04/12/2016. We identified any relevant AEIs, as specified by EMA, up to 7 days post-vaccination. We produced overall rates for each brand.Results76.3% of vaccinated patients had an identified brand; out of these, 3.7% had an AEI. Brand A had a share of 9.6% (95%CI 9.5-9.7) of the vaccines, and 7.4% (95%CI 6.9-7.9) of the AEIs. Brand B had 29.1% (95%CI 28.9-29.3) of the vaccines, and 28.8% (95%CI 27.9-29.7) of the AEIs. Brand C had 44.9% (95%CI 44.7-45.0) of the vaccines, and 41.0% (95%CI 40.0-42.0) of the AEIs. Brand D had 9.3% (95%CI 9.1-9.4) of the vaccines, and 10.1% (95%CI 9.5-10.7) of the AEIs. Brand E had 7.2% (95%CI 7.1-7.2) of the vaccines, and 12.7% (95%CI 12.1-13.4) of the AEIs.ConclusionBrand A and C had a significantly lower proportion of AEIs compared to their share of vaccines, while the opposite was true for Brand D and E. Further work will explore the feasibility of using the self-controlled case series method to quantify the level of brand-specific risk of AEIs. External funding details The RCGP RSC work is primarily funded by PHE.
Abstract IntroductionThe European Medicines Agency (EMA) has released guidance for the surveillance of adverse events of interest (AEIs) following vaccination, early in the influenza season. It is feasible to capture brand-specific AEIs using a sentinel practice network, such as the Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC).MethodUsing the RCGP RSC dataset, we identified brands for 344,542 patients receiving the seasonal influenza from 01/09/2016 to 04/12/2016. We identified any relevant AEIs, as specified by EMA, up to 7 days post-vaccination. We produced overall rates for each brand.Results76.3% of vaccinated patients had an identified brand; out of these, 3.7% had an AEI. Brand A had a share of 9.6% (95%CI 9.5-9.7) of the vaccines, and 7.4% (95%CI 6.9-7.9) of the AEIs. Brand B had 29.1% (95%CI 28.9-29.3) of the vaccines, and 28.8% (95%CI 27.9-29.7) of the AEIs. Brand C had 44.9% (95%CI 44.7-45.0) of the vaccines, and 41.0% (95%CI 40.0-42.0) of the AEIs. Brand D had 9.3% (95%CI 9.1-9.4) of the vaccines, and 10.1% (95%CI 9.5-10.7) of the AEIs. Brand E had 7.2% (95%CI 7.1-7.2) of the vaccines, and 12.7% (95%CI 12.1-13.4) of the AEIs.ConclusionBrand A and C had a significantly lower proportion of AEIs compared to their share of vaccines, while the opposite was true for Brand D and E. Further work will explore the feasibility of using the self-controlled case series method to quantify the level of brand-specific risk of AEIs. External funding details The RCGP RSC work is primarily funded by PHE.
By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS). USER TERMS AND CONDITIONS | PRIVACY POLICY
Cookie Settings
Accept Terms & all Cookies
Anonymous User Privacy Preferences
Strictly Necessary Cookies (Always Active)
MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.
Performance Cookies
Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.